Free Trial
→ Today's free pick (on me) (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$0.96
+0.9%		$0.95
$2.03
▼
$5.50
$116.69M0.16216,519 shs200 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$2.33
-2.1%		$3.06
$1.96
▼
$8.80
$116.15M0.09204,914 shs19,158 shs
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
$2.89
-4.0%		$2.75
$2.01
▼
$5.38
$116.76M0.18272,616 shs97,291 shs
Vermillion, Inc. stock logo
VRML
Vermillion
$0.30
+6.8%		$3.26
$0.35
▼
$5.78
$29.21M3.47440,144 shs24,099 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Global Cord Blood Co. stock logo
CO
Global Cord Blood
0.00%0.00%0.00%0.00%+26.80%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-7.03%+3.48%-5.56%-48.03%-40.50%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-10.42%+18.97%+28.09%-24.56%-2.27%
Vermillion, Inc. stock logo
VRML
Vermillion
0.00%0.00%0.00%0.00%-40.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$0.96
+0.9%		$0.95
$2.03
▼
$5.50
$116.69M0.16216,519 shs200 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$2.33
-2.1%		$3.06
$1.96
▼
$8.80
$116.15M0.09204,914 shs19,158 shs
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
$2.89
-4.0%		$2.75
$2.01
▼
$5.38
$116.76M0.18272,616 shs97,291 shs
Vermillion, Inc. stock logo
VRML
Vermillion
$0.30
+6.8%		$3.26
$0.35
▼
$5.78
$29.21M3.47440,144 shs24,099 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Global Cord Blood Co. stock logo
CO
Global Cord Blood
0.00%0.00%0.00%0.00%+26.80%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-7.03%+3.48%-5.56%-48.03%-40.50%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-10.42%+18.97%+28.09%-24.56%-2.27%
Vermillion, Inc. stock logo
VRML
Vermillion
0.00%0.00%0.00%0.00%-40.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Global Cord Blood Co. stock logo
CO
Global Cord Blood
0.00
N/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$10.33343.30% Upside
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
2.25
Hold$17.50505.54% Upside
Vermillion, Inc. stock logo
VRML
Vermillion
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VRML, OKUR, CO, and NERV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/26/2026
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/9/2026
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/9/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
9/21/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/21/2026
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/14/2026
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$14.00
8/14/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Mixed$7.50 ➝ $10.00
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$1.24B0.09$0.23 per share4.19$6.34 per share0.15
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($1.96) per shareN/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/AN/AN/AN/A$3.90 per shareN/A
Vermillion, Inc. stock logo
VRML
Vermillion
$4.54M6.43N/AN/A$0.09 per share3.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$79.04M$0.641.50N/AN/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$28.70N/AN/AN/AN/AN/A-28.95%N/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-$59.52M-$2.77N/AN/AN/AN/A-43.38%-40.74%N/A
Vermillion, Inc. stock logo
VRML
Vermillion
-$15.24MN/AN/AN/AN/A-307.31%-155.25%-103.47%N/A

Latest VRML, OKUR, CO, and NERV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.14-$1.60-$1.46-$0.0750N/AN/A
11/4/2026Q3 2026
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-$0.4067-$0.36+$0.0467-$0.36$0.17 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$0.088.33%N/A12.50%N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/AN/AN/AN/AN/A
Vermillion, Inc. stock logo
VRML
Vermillion
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Global Cord Blood Co. stock logo
CO
Global Cord Blood
N/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
33.02
20.14
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/A
18.84
18.84
Vermillion, Inc. stock logo
VRML
Vermillion
0.20
2.51
2.49

Institutional Ownership

CompanyInstitutional Ownership
Global Cord Blood Co. stock logo
CO
Global Cord Blood
N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
90.98%
Vermillion, Inc. stock logo
VRML
Vermillion
18.09%

Insider Ownership

CompanyInsider Ownership
Global Cord Blood Co. stock logo
CO
Global Cord Blood
0.50%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.70%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
2.17%
Vermillion, Inc. stock logo
VRML
Vermillion
4.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Global Cord Blood Co. stock logo
CO
Global Cord Blood
1,202121.55 millionN/ANo Data
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
749.83 million48.99 millionOptionable
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
4540.40 million39.52 millionOptionable
Vermillion, Inc. stock logo
VRML
Vermillion
4397.38 millionN/ANot Optionable

Recent News About These Companies

Vermillion authorities investigate car vs building crash
August 10, 2024  |  keloland.comK
2023 HW Vanguard: Dale Vermillion
October 15, 2023  |  housingwire.comH
Goodwill coming to Vermillion
September 17, 2023  |  siouxcityjournal.comS
In Telangana, Vermillion And Saffron Threads Were Used To Lure Women Voters
September 2, 2023  |  outlookindia.comhttps://www.outlookindia.com/national/telangana-rss-offered-vermillion-and-saffron-threads-to-gain-trust-of-women-voters-magazine-301282
Vermillion, SD 10-Day Weather Forecast
July 17, 2023  |  wunderground.comW
A cold case without a crime: Inside the messy investigation into two missing SD teens in 1971
June 21, 2023  |  grandforksherald.comG
Camellia Vermillion
June 16, 2023  |  health.usnews.comhttps://health.usnews.com/nurse-practitioners/camellia-vermillion-2017770
Dr. Richard L. Knutson
June 6, 2023  |  health.usnews.comhttps://health.usnews.com/dentists/richard-knutson-1784514
Vermillion Elementary School
May 24, 2023  |  usnews.comhttps://www.usnews.com/education/k12/kansas/vermillion-elementary-school-224797
Dr. Kenneth J. Vermillion
May 20, 2023  |  health.usnews.comhttps://health.usnews.com/dentists/kenneth-vermillion-1621386
Golf: Vermillion Runner-Up At Huskies Invitational | Sports | plaintalk ... - Vermillion Plain Talk
May 13, 2023  |  news.google.comN
Driver killed after veering into path of dump truck on Highway 52 - Bring Me The News
May 13, 2023  |  news.google.comN
Fatal crash in Vermillion Township closes portion of Highway 52 - CBS News
May 13, 2023  |  news.google.comN
Vermillion, KS Weather Conditions
May 13, 2023  |  wunderground.comW
Vermillion Softball Falls To Tea Area 12-2 | Sports | plaintalk.net - Vermillion Plain Talk
May 13, 2023  |  news.google.comN
Baseball: Dakota Valley Blanks Vermillion 7-0 | Sports | plaintalk.net - Vermillion Plain Talk
May 13, 2023  |  news.google.comN
Vermillion High School
May 12, 2023  |  usnews.comhttps://www.usnews.com/education/best-high-schools/south-dakota/districts/vermillion-school-district-13-1/vermillion-high-school-17894
Track: Chargers Sweep Dakota XII Conference Titles | Sports - Yankton Daily Press
May 11, 2023  |  news.google.comN
PREP ROUNDUP: Nevill selected as Northview boys basketball coach - Terre Haute Tribune Star
May 11, 2023  |  news.google.comN
PREP TRACK: WRC Championship results | Sports - Danville Commercial News
May 11, 2023  |  news.google.comN

Media Sentiment Over Time

Top Headlines

View All Headlines
White Tesla sports car parked at a launch site with rocket boosters visible against a sunset sky.
Tesla's Roadster Reveal Hints at 2 Much Bigger Moves
By Sam Quirke | October 19, 2026
Industrial energy facility with cooling units, piping systems, and a large turbine beside flowing water.
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
By Chris Markoch | October 18, 2026
Illuminated Tesla logo in a factory setting with robotic machinery and a semiconductor wafer in the foreground.
Tesla Wants to Make Its Own Chips—What Could Go Wrong?
By Sam Quirke | October 14, 2026
Kinder Morgan logo over pipelines and an energy processing facility at sunset.
Why Kinder Morgan's Chairman Just Bought $15 Million in Stock
By Jeffrey Neal Johnson | November 10, 2026
Newmont logo over an open-pit mine with haul trucks and excavation equipment at sunset.
Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
By Chris Markoch | October 25, 2026
Global Cord Blood stock logo

Global Cord Blood NYSE:CO

$0.96 +0.01 (+0.95%)
As of 11/12/2026

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$2.33 -0.05 (-2.06%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

OnKure Therapeutics stock logo

OnKure Therapeutics NASDAQ:OKUR

$2.89 -0.12 (-3.99%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Vermillion stock logo

Vermillion NASDAQ:VRML

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas